Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Carlyle Group Inc.CG · Entity 3316 | Director | September 11, 2026 | September 11, 2026 |
| Moderna, Inc.MRNA · Entity 2025 | Director | May 06, 2026 | May 08, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Carlyle Group Inc.
Report date September 11, 2026 · Filed September 11, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 26,899,644 |
Ending reported balance
After 2026-09-11 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-09-11 · Gift · Disposed 100,000 · Balance 27,299,644 F1: Reflects a charitable donation by the Reporting Person. Row 2 · 2026-09-11 · Sale · Disposed 400,000 · Balance 26,899,644 F2: The price reported in column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $42.74 to $42.93, inclusive. The Reporting Person undertakes to provide to The Carlyle Group Inc., any security holder of The Carlyle Group Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares of common stock sold at each separate price within the range set forth in this footnote. |
Filing footnotes · ownership attribution and instrument terms
F1: Reflects a charitable donation by the Reporting Person.
F2: The price reported in column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $42.74 to $42.93, inclusive. The Reporting Person undertakes to provide to The Carlyle Group Inc., any security holder of The Carlyle Group Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares of common stock sold at each separate price within the range set forth in this footnote.
Moderna, Inc.
Report date May 06, 2026 · Filed May 08, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $48.79 · Expires 2036-05-06 | Direct | 9,681 |
Reported balance
After 2026-05-06 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-05-06 · Grant · Acquired 9,681 · Balance 9,681 F1: This option will become fully vested and exercisable on the earlier of May 6, 2027, or Moderna's next Annual Meeting of Shareholders, subject to the recipient's continued service. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 2,092 |
Reported balance
After 2026-05-06 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-05-06 · Grant · Acquired 2,092 · Balance 2,092 F2: Restricted stock units convert into common stock on a one-for-one basis. F3: The shares subject to this restricted stock unit award will vest in full on the earlier of May 6, 2027, or Moderna's next Annual Meeting of Shareholders, subject to the recipient's continued service. |
Filing footnotes · ownership attribution and instrument terms
F1: This option will become fully vested and exercisable on the earlier of May 6, 2027, or Moderna's next Annual Meeting of Shareholders, subject to the recipient's continued service.
F2: Restricted stock units convert into common stock on a one-for-one basis.
F3: The shares subject to this restricted stock unit award will vest in full on the earlier of May 6, 2027, or Moderna's next Annual Meeting of Shareholders, subject to the recipient's continued service.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 11, 2026 Filed Sep 11, 2026 21:11 UTC | Carlyle Group Inc. CG · Entity 3316 | SaleCommon Stock | 400,000 | $42.74 | $17,096,000.00 |
DisclosureSEC source: 0001543895-26-000004 · wk-form4_1789161096.xml · nonDerivative · entry 2 Rubenstein David M. · CIK 0001543895 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,899,644 F2 · price: The price reported in column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $42.74 to $42.93, inclusive. The Reporting Person undertakes to provide to The Carlyle Group Inc., any security holder of The Carlyle Group Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares of common stock sold at each separate price within the range set forth in this footnote. Read SEC document |
| September 11, 2026 Filed Sep 11, 2026 21:11 UTC | Carlyle Group Inc. CG · Entity 3316 | GiftCommon Stock | 100,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001543895-26-000004 · wk-form4_1789161096.xml · nonDerivative · entry 1 Rubenstein David M. · CIK 0001543895 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,299,644 F1 · kind: Reflects a charitable donation by the Reporting Person. Read SEC document |
| May 06, 2026 Filed May 8, 2026 21:07 UTC | Moderna, Inc. MRNA · Entity 2025 | GrantRestricted Stock Units · Derivative | 2,092 | $0.00 | $0.00 |
DisclosureSEC source: 0001682852-26-000097 · form4.xml · derivative · entry 2 Rubenstein David M. · CIK 0001543895 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,092 Underlying: Common Stock · 2,092 shares Expires not disclosed F2 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F3 · derivative.exercise_date: The shares subject to this restricted stock unit award will vest in full on the earlier of May 6, 2027, or Moderna's next Annual Meeting of Shareholders, subject to the recipient's continued service. F3 · derivative.expiration_date: The shares subject to this restricted stock unit award will vest in full on the earlier of May 6, 2027, or Moderna's next Annual Meeting of Shareholders, subject to the recipient's continued service. Read SEC document |
| May 06, 2026 Filed May 8, 2026 21:07 UTC | Moderna, Inc. MRNA · Entity 2025 | GrantStock Option (Right to Buy) · Derivative | 9,681 | $0.00 Strike: $48.79 | $0.00 |
DisclosureSEC source: 0001682852-26-000097 · form4.xml · derivative · entry 1 Rubenstein David M. · CIK 0001543895 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,681 Underlying: Common Stock · 9,681 shares Expires 2036-05-06 F1 · derivative.exercise_date: This option will become fully vested and exercisable on the earlier of May 6, 2027, or Moderna's next Annual Meeting of Shareholders, subject to the recipient's continued service. Read SEC document |
| April 30, 2026 Filed May 4, 2026 21:36 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionRestricted Stock Units · Derivative | 8,116 | $0.00 | $0.00 |
DisclosureSEC source: 0001682852-26-000073 · form4.xml · derivative · entry 2 Rubenstein David M. · CIK 0001543895 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 8,116 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F1 · kind: Restricted stock units convert into common stock on a one-for-one basis. F2 · derivative.exercise_date: The shares subject to this restricted stock unit award vested in full on April 30, 2026. F2 · derivative.expiration_date: The shares subject to this restricted stock unit award vested in full on April 30, 2026. Read SEC document |
| April 30, 2026 Filed May 4, 2026 21:36 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionCommon Stock | 8,116 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001682852-26-000073 · form4.xml · nonDerivative · entry 1 Rubenstein David M. · CIK 0001543895 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,643 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Restricted stock units convert into common stock on a one-for-one basis. F1 · price: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document |
| March 19, 2026 Filed Mar 20, 2026 21:34 UTC | Carlyle Group Inc. CG · Entity 3316 | SaleCommon Stock | 500,000 | $46.68 | $23,340,000.00 |
DisclosureSEC source: 0001543895-26-000002 · wk-form4_1774042450.xml · nonDerivative · entry 2 Rubenstein David M. · CIK 0001543895 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,399,644 Read SEC document |
| March 19, 2026 Filed Mar 20, 2026 21:34 UTC | Carlyle Group Inc. CG · Entity 3316 | GiftCommon Stock | 100,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001543895-26-000002 · wk-form4_1774042450.xml · nonDerivative · entry 1 Rubenstein David M. · CIK 0001543895 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,899,644 F1 · kind: Reflects a charitable donation by the Reporting Person. Read SEC document |
| December 10, 2025 Filed Dec 12, 2025 22:35 UTC | Carlyle Group Inc. CG · Entity 3316 | SaleCommon Stock | 625,000 | $56.55 | $35,343,750.00 |
DisclosureSEC source: 0001543895-25-000007 · wk-form4_1765578914.xml · nonDerivative · entry 2 Rubenstein David M. · CIK 0001543895 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,999,644 Read SEC document |
| December 10, 2025 Filed Dec 12, 2025 22:35 UTC | Carlyle Group Inc. CG · Entity 3316 | GiftCommon Stock | 625,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001543895-25-000007 · wk-form4_1765578914.xml · nonDerivative · entry 1 Rubenstein David M. · CIK 0001543895 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 28,624,644 F1 · kind: Reflects a charitable donation by the Reporting Person. Read SEC document |
| August 05, 2025 Filed Aug 6, 2025 20:06 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionRestricted Stock Units · Derivative | 850 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-25-020157 · form4.xml · derivative · entry 2 Rubenstein David M. · CIK 0001543895 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 850 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F1 · kind: Restricted stock units convert into common stock on a one-for-one basis. F2 · derivative.exercise_date: The shares subject to this restricted stock unit award vested in full on August 5, 2025. F2 · derivative.expiration_date: The shares subject to this restricted stock unit award vested in full on August 5, 2025. Read SEC document |
| August 05, 2025 Filed Aug 6, 2025 20:06 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionCommon Stock | 850 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-25-020157 · form4.xml · nonDerivative · entry 1 Rubenstein David M. · CIK 0001543895 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,527 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Restricted stock units convert into common stock on a one-for-one basis. F1 · price: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document |
| April 30, 2025 Filed May 1, 2025 20:34 UTC | Moderna, Inc. MRNA · Entity 2025 | GrantRestricted Stock Units · Derivative | 8,116 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-25-012943 · form4.xml · derivative · entry 4 Rubenstein David M. · CIK 0001543895 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,116 Underlying: Common Stock · 8,116 shares Expires not disclosed F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F4 · derivative.exercise_date: The shares subject to this restricted stock unit award will vest in full on the earlier of April 30, 2026, or Moderna's next Annual Meeting of Shareholders, subject to the recipient's continued service. F4 · derivative.expiration_date: The shares subject to this restricted stock unit award will vest in full on the earlier of April 30, 2026, or Moderna's next Annual Meeting of Shareholders, subject to the recipient's continued service. Read SEC document |
| April 30, 2025 Filed May 1, 2025 20:34 UTC | Moderna, Inc. MRNA · Entity 2025 | GrantStock Option (Right to Buy) · Derivative | 12,756 | $0.00 Strike: $28.54 | $0.00 |
DisclosureSEC source: 0001127602-25-012943 · form4.xml · derivative · entry 3 Rubenstein David M. · CIK 0001543895 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,756 Underlying: Common Stock · 12,756 shares Expires 2035-04-30 F3 · derivative.exercise_date: This option will become fully vested and exercisable on the earlier of April 30, 2026, or Moderna's next Annual Meeting of Shareholders, subject to the recipient's continued service. Read SEC document |
| April 30, 2025 Filed May 1, 2025 20:34 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionRestricted Stock Units · Derivative | 677 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-25-012943 · form4.xml · derivative · entry 2 Rubenstein David M. · CIK 0001543895 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 677 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F1 · kind: Restricted stock units convert into common stock on a one-for-one basis. F2 · derivative.exercise_date: The shares subject to this restricted stock unit award vested in full on April 30, 2025. F2 · derivative.expiration_date: The shares subject to this restricted stock unit award vested in full on April 30, 2025. Read SEC document |
| April 30, 2025 Filed May 1, 2025 20:34 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionCommon Stock | 677 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-25-012943 · form4.xml · nonDerivative · entry 1 Rubenstein David M. · CIK 0001543895 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 677 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Restricted stock units convert into common stock on a one-for-one basis. F1 · price: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document |
| August 05, 2024 Filed Aug 7, 2024 20:06 UTC | Moderna, Inc. MRNA · Entity 2025 | GrantRestricted Stock Units · Derivative | 677 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-24-021791 · form4.xml · derivative · entry 4 Rubenstein David M. · CIK 0001543895 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 677 Underlying: Common Stock · 677 shares Expires not disclosed F3 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F5 · derivative.exercise_date: The shares subject to this restricted stock unit award will vest in full on the earlier of May 6, 2025, or Moderna's next Annual Meeting of Stockholders, subject to the recipient's continued service. F5 · derivative.expiration_date: The shares subject to this restricted stock unit award will vest in full on the earlier of May 6, 2025, or Moderna's next Annual Meeting of Stockholders, subject to the recipient's continued service. Read SEC document |
| August 05, 2024 Filed Aug 7, 2024 20:06 UTC | Moderna, Inc. MRNA · Entity 2025 | GrantRestricted Stock Units · Derivative | 850 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-24-021791 · form4.xml · derivative · entry 3 Rubenstein David M. · CIK 0001543895 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 850 Underlying: Common Stock · 850 shares Expires not disclosed F3 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F4 · derivative.exercise_date: The shares subject to this restricted stock unit award will vest in full on August 5, 2025. F4 · derivative.expiration_date: The shares subject to this restricted stock unit award will vest in full on August 5, 2025. Read SEC document |
| August 05, 2024 Filed Aug 7, 2024 20:06 UTC | Moderna, Inc. MRNA · Entity 2025 | GrantStock Option (Right to Buy) · Derivative | 4,065 | $0.00 Strike: $83.75 | $0.00 |
DisclosureSEC source: 0001127602-24-021791 · form4.xml · derivative · entry 2 Rubenstein David M. · CIK 0001543895 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,065 Underlying: Common Stock · 4,065 shares Expires 2034-08-05 F2 · derivative.exercise_date: This option will become fully vested and exercisable on the earlier of May 6, 2025, or Moderna's next Annual Meeting of Stockholders, subject to the recipient's continued service. Read SEC document |
| August 05, 2024 Filed Aug 7, 2024 20:06 UTC | Moderna, Inc. MRNA · Entity 2025 | GrantStock Option (Right to Buy) · Derivative | 5,051 | $0.00 Strike: $83.75 | $0.00 |
DisclosureSEC source: 0001127602-24-021791 · form4.xml · derivative · entry 1 Rubenstein David M. · CIK 0001543895 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,051 Underlying: Common Stock · 5,051 shares Expires 2034-08-05 F1 · derivative.exercise_date: This option will become fully vested and exercisable on August 5, 2025. Read SEC document |
| June 06, 2022 Filed Jun 6, 2022 20:30 UTC | Carlyle Group Inc. CG · Entity 3316 | SaleCommon Stock | 2,000,000 | $38.67 | $77,340,000.00 |
DisclosureSEC source: 0000899243-22-021197 · doc4.xml · nonDerivative · entry 1 Rubenstein David M. · CIK 0001543895 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,249,644 Read SEC document |
| November 09, 2021 Filed Nov 10, 2021 22:52 UTC | Carlyle Group Inc. CG · Entity 3316 | SaleCommon Stock | 2,000,000 | $58.00 | $116,000,000.00 |
DisclosureSEC source: 0000899243-21-044023 · doc4.xml · nonDerivative · entry 1 Rubenstein David M. · CIK 0001543895 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,249,644 Read SEC document |
| August 13, 2021 Filed Aug 14, 2021 01:14 UTC | Carlyle Group Inc. CG · Entity 3316 | SaleCommon Stock | 4,800 | $48.86 | $234,528.00 |
DisclosureSEC source: 0000899243-21-033055 · doc4.xml · nonDerivative · entry 3 Rubenstein David M. · CIK 0001543895 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,249,644 F1 · price: The price reported in column 4 is a weighted average price. These shares of common stock were sold in multiple transactions at prices ranging from $48.83 to $48.88, inclusive. The reporting person undertakes to provide to The Carlyle Group Inc., any security holder of The Carlyle Group Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares of common stock sold at each separate price within the range set forth in this footnote. Read SEC document |
| August 13, 2021 Filed Aug 14, 2021 01:14 UTC | Carlyle Group Inc. CG · Entity 3316 | SaleCommon Stock | 1,895,200 | $47.80 | $90,590,560.00 |
DisclosureSEC source: 0000899243-21-033055 · doc4.xml · nonDerivative · entry 2 Rubenstein David M. · CIK 0001543895 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,254,444 Read SEC document |
| August 11, 2021 Filed Aug 14, 2021 01:14 UTC | Carlyle Group Inc. CG · Entity 3316 | SaleCommon Stock | 2,100,000 | $46.46 | $97,566,000.00 |
DisclosureSEC source: 0000899243-21-033055 · doc4.xml · nonDerivative · entry 1 Rubenstein David M. · CIK 0001543895 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,149,644 Read SEC document |
| May 18, 2021 Filed May 19, 2021 22:15 UTC | Carlyle Group Inc. CG · Entity 3316 | SaleCommon Stock | 2,000,000 | $41.76 | $83,520,000.00 |
DisclosureSEC source: 0000899243-21-019973 · doc4.xml · nonDerivative · entry 1 Rubenstein David M. · CIK 0001543895 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,249,644 Read SEC document |
| March 11, 2021 Filed Mar 13, 2021 01:09 UTC | Carlyle Group Inc. CG · Entity 3316 | SaleCommon Stock | 3,000,000 | $35.80 | $107,400,000.00 |
DisclosureSEC source: 0000899243-21-011440 · doc4.xml · nonDerivative · entry 1 Rubenstein David M. · CIK 0001543895 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,249,644 Read SEC document |
| December 10, 2020 Filed Dec 11, 2020 23:02 UTC | Carlyle Group Inc. CG · Entity 3316 | SaleCommon Stock | 750,000 | $29.05 | $21,787,500.00 |
DisclosureSEC source: 0000899243-20-033599 · doc4.xml · nonDerivative · entry 1 Rubenstein David M. · CIK 0001543895 · Director · See Remarks · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,249,644 F1 · price: The price reported in column 4 is a weighted average price. These shares of common stock were sold in multiple transactions at prices ranging from $29.05 to $29.76, inclusive. The reporting person undertakes to provide to The Carlyle Group Inc., any security holder of The Carlyle Group Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares of common stock sold at each separate price within the range set forth in this footnote. Read SEC document |
| November 24, 2020 Filed Nov 24, 2020 22:29 UTC | Carlyle Group Inc. CG · Entity 3316 | SaleCommon Stock | 2,000,000 | $27.30 | $54,600,000.00 |
DisclosureSEC source: 0000899243-20-032047 · doc4.xml · nonDerivative · entry 1 Rubenstein David M. · CIK 0001543895 · Director · See Remarks · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,999,644 Read SEC document |
| November 09, 2020 Filed Nov 10, 2020 21:43 UTC | Carlyle Group Inc. CG · Entity 3316 | SaleCommon Stock | 2,000,000 | $27.32 | $54,640,000.00 |
DisclosureSEC source: 0000899243-20-030734 · doc4.xml · nonDerivative · entry 1 Rubenstein David M. · CIK 0001543895 · Director · See Remarks · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,999,644 Read SEC document |
| January 01, 2020 Filed Jan 3, 2020 22:10 UTC | Carlyle Group Inc. CG · Entity 3316 | ConversionCarlyle Holdings partnership units · Derivative | 46,999,644 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-20-000292 · doc4.xml · derivative · entry 2 Rubenstein David M. · CIK 0001543895 · Director · See Remarks · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Units Representing limited partnership interests · 46,999,644 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Pursuant to the terms of the exchange agreement and subject to certain requirements and restrictions, the partnership units of Carlyle Holdings were exchangeable for common units of The Carlyle Group L.P. on a one-for-one basis. F1 · kind: On January 1, 2020, The Carlyle Group L.P., a Delaware limited partnership, converted into a Delaware corporation named The Carlyle Group Inc. (the "Conversion"). As a result of such conversion, each common unit of limited partner interest of The Carlyle Group L.P. converted into a share of common stock of The Carlyle Group Inc. (the "Common Stock"). F2 · kind: Pursuant to the terms of the Conversion, partnership units of Carlyle Holdings were exchanged for shares of Common Stock on a one-for-one basis. F1 · price: On January 1, 2020, The Carlyle Group L.P., a Delaware limited partnership, converted into a Delaware corporation named The Carlyle Group Inc. (the "Conversion"). As a result of such conversion, each common unit of limited partner interest of The Carlyle Group L.P. converted into a share of common stock of The Carlyle Group Inc. (the "Common Stock"). F2 · price: Pursuant to the terms of the Conversion, partnership units of Carlyle Holdings were exchanged for shares of Common Stock on a one-for-one basis. F3 · derivative.exercise_date: Pursuant to the terms of the exchange agreement and subject to certain requirements and restrictions, the partnership units of Carlyle Holdings were exchangeable for common units of The Carlyle Group L.P. on a one-for-one basis. F3 · derivative.expiration_date: Pursuant to the terms of the exchange agreement and subject to certain requirements and restrictions, the partnership units of Carlyle Holdings were exchangeable for common units of The Carlyle Group L.P. on a one-for-one basis. Read SEC document |
| January 01, 2020 Filed Jan 3, 2020 22:10 UTC | Carlyle Group Inc. CG · Entity 3316 | ConversionCommon Stock | 46,999,644 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-000292 · doc4.xml · nonDerivative · entry 1 Rubenstein David M. · CIK 0001543895 · Director · See Remarks · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,999,644 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: On January 1, 2020, The Carlyle Group L.P., a Delaware limited partnership, converted into a Delaware corporation named The Carlyle Group Inc. (the "Conversion"). As a result of such conversion, each common unit of limited partner interest of The Carlyle Group L.P. converted into a share of common stock of The Carlyle Group Inc. (the "Common Stock"). F1 · kind: On January 1, 2020, The Carlyle Group L.P., a Delaware limited partnership, converted into a Delaware corporation named The Carlyle Group Inc. (the "Conversion"). As a result of such conversion, each common unit of limited partner interest of The Carlyle Group L.P. converted into a share of common stock of The Carlyle Group Inc. (the "Common Stock"). F2 · kind: Pursuant to the terms of the Conversion, partnership units of Carlyle Holdings were exchanged for shares of Common Stock on a one-for-one basis. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.